+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vasculitis Treatment Market - Global Forecast 2026-2032- Product Image
Vasculitis Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Vasculitis Treatment Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888985
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Vasculitis Treatment Market is projected to reach USD 1.75 Billion in 2026. It is expected to continue growing at a CAGR of 5.31%, reaching USD 2.39 Billion by 2032.

Vasculitis treatment addresses a diverse group of inflammatory disorders affecting blood vessels and, in some cases, multiple organs. Clinical management is shaped by disease subtype, severity, organ involvement, relapse risk, comorbidities, and treatment-related toxicity. Care commonly combines diagnostic confirmation, induction of remission, maintenance therapy, monitoring, and supportive management. Because presentation can resemble infection, malignancy, or other autoimmune disease, timely specialist evaluation and coordinated multidisciplinary care are central to improving outcomes.

Treatment Is Shifting Toward Precision and Long-Term Disease Control

The treatment landscape is moving from broad immunosuppression alone toward more individualized care. Classification by vessel size and clinical phenotype, improved use of imaging and laboratory testing, and clearer separation of induction from maintenance strategies support more targeted decisions. Clinicians are also placing greater emphasis on relapse prevention, steroid minimization, infection prevention, bone health, fertility considerations, cardiovascular risk, and patient-reported quality of life. Access to specialist services and consistent follow-up remains essential because disease activity and treatment toxicity can evolve over time.

Artificial Intelligence Strengthens Detection, Monitoring, and Treatment Support

Artificial intelligence can contribute to vasculitis care by identifying patterns in imaging, pathology, laboratory results, and longitudinal clinical records. Potential applications include earlier recognition of organ-threatening disease, assistance with subtype classification, relapse-risk stratification, and monitoring for adverse effects. Its practical value depends on representative datasets, transparent validation, clinician oversight, interoperability, and safeguards for privacy and bias. AI should support-not replace-expert judgment, particularly when symptoms are nonspecific or urgent treatment decisions are required.

Regional Priorities Reflect Uneven Specialist Access and Diagnostic Capacity

North America generally benefits from established specialty networks, advanced diagnostics, and broad access to biologic and immunomodulatory therapies, although affordability and regional disparities remain important concerns. Europe combines strong clinical research and guideline infrastructure with variation in reimbursement, referral pathways, and access across countries. Asia-Pacific includes sophisticated specialist systems alongside settings where delayed recognition, limited testing, and workforce constraints are more pronounced. Latin America faces differences in public and private coverage, medicine availability, and specialist concentration. In the Middle East, referral capacity and access to advanced diagnostics vary substantially between health systems. Africa continues to require stronger diagnostic infrastructure, specialist training, reliable medicine supply, and integrated referral pathways.

Multilateral Groups Can Align Standards, Access, and Evidence Generation

ASEAN cooperation can support shared training, referral networks, and approaches suited to diverse health systems. BRICS members can advance collaborative research, diagnostic capacity, and affordable access while accounting for substantial differences in national resources. The European Union can strengthen cross-border care, harmonized evidence standards, and equitable implementation of clinical guidance. G7 countries can contribute to innovation, pharmacovigilance, and evidence on long-term safety. GCC health systems can build regional centers of expertise and coordinated pathways for complex disease. NATO members can also benefit from interoperable clinical preparedness, trauma-informed referral capabilities, and continuity of care for mobile populations.

Country-Level Needs Range From Innovation Leadership to Foundational Capacity Building

Australia can build on specialist services and geographically connected care models to improve access outside major cities. Brazil and Mexico would benefit from stronger referral pathways, diagnostic availability, and consistent access across public and private settings. Canada and the United States can focus on affordability, rural access, and coordinated long-term monitoring. China and India have opportunities to expand specialist capacity, standardized diagnosis, and locally relevant evidence across varied regions. Japan and South Korea can leverage advanced healthcare infrastructure while addressing aging populations and continuity of care. France, Germany, Italy, Spain, and the United Kingdom can continue refining early referral, steroid-sparing care, registry use, and equitable access within established systems. Russia faces the importance of sustained specialist availability, reliable diagnostics, and treatment continuity across geographically dispersed populations.

Leadership Priorities for More Effective Vasculitis Care

Industry leaders should prioritize therapies and services that address clearly defined disease subtypes, organ-threatening presentations, relapse prevention, and treatment toxicity. Evidence strategies should include meaningful clinical outcomes, long-term safety, quality of life, and representation across relevant populations. Partnerships with specialist centers can improve diagnostic education, referral speed, and real-world monitoring. Responsible AI development should use clinically validated datasets and explainable workflows. Access planning should account for affordability, cold-chain or administration requirements, local clinical capacity, patient support, and continuity during transitions between care settings.

Methodology for a Clinically Grounded Executive Summary

This summary uses the supplied market scope-vasculitis treatment-as its organizing framework and synthesizes established clinical considerations across disease recognition, treatment pathways, monitoring, technology, and health-system access. Regional, group, and country narratives are comparative and qualitative, reflecting differences in specialist capacity, diagnostic infrastructure, reimbursement, research activity, and care delivery. No market estimates, forecasts, market shares, or company-specific claims are included. Interpretation should be complemented by current clinical guidelines, regulatory information, peer-reviewed evidence, and local treatment protocols.

Integrated Care and Equitable Access Define the Next Phase

Vasculitis treatment is increasingly centered on rapid, accurate classification; individualized induction and maintenance; prevention of relapse and treatment harm; and sustained, multidisciplinary follow-up. Advances in diagnostics, biologic and immunomodulatory strategies, data systems, and AI may strengthen care when implemented with rigorous evidence and clinical governance. The most durable progress will depend on connecting innovation with specialist training, reliable access, patient engagement, and health-system capacity across regions and countries.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Vasculitis Treatment Market, by Treatment Type
7.1. Introduction
7.2. Biologics
7.2.1. Rituximab
7.2.2. Tumor Necrosis Factor Inhibitors
7.3. Corticosteroids
7.4. Immunosuppressants
7.4.1. Azathioprine
7.4.2. Cyclophosphamide
7.4.3. Methotrexate
7.4.4. Mycophenolate Mofetil
7.5. Plasma Exchange
8. Vasculitis Treatment Market, by Administration Route
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous
9. Vasculitis Treatment Market, by Disease Type
9.1. Introduction
9.2. ANCA Associated Vasculitis
9.3. Behcet Disease
9.4. Giant Cell Arteritis
9.5. IgA Vasculitis
9.6. Takayasu Arteritis
10. Vasculitis Treatment Market, by End User
10.1. Introduction
10.2. Ambulatory Care Centers
10.3. Clinics
10.4. Hospitals
10.5. Specialty Centers
11. Vasculitis Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Vasculitis Treatment Market, by Region
12.1. Introduction
12.2. Europe
12.3. Asia-Pacific
12.4. North America
12.5. Latin America
12.6. Middle East
12.7. Africa
13. Vasculitis Treatment Market, by Group
13.1. Introduction
13.2. NATO
13.3. G7
13.4. European Union
13.5. BRICS
13.6. ASEAN
13.7. GCC
14. Vasculitis Treatment Market, by Country
14.1. Introduction
14.2. United States
14.3. China
14.4. Germany
14.5. Japan
14.6. United Kingdom
14.7. India
14.8. France
14.9. Canada
14.10. Brazil
14.11. Mexico
14.12. Italy
14.13. Spain
14.14. Australia
14.15. South Korea
14.16. Russia
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
17. Key Experts
List of Figures
FIGURE 1. Global Vasculitis Treatment Market, Years Considered for the Study
FIGURE 2. Global Vasculitis Treatment Market, Research Design
FIGURE 3. Global Vasculitis Treatment Market, Research Framework
FIGURE 4. Global Vasculitis Treatment Market, Data Triangulation
FIGURE 5. Global Vasculitis Treatment Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Vasculitis Treatment Market Size, by Treatment Type, 2025 vs 2032 (%)
FIGURE 7. Global Vasculitis Treatment Market Size, by Treatment Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Vasculitis Treatment Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 9. Global Vasculitis Treatment Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Vasculitis Treatment Market Size, by Disease Type, 2025 vs 2032 (%)
FIGURE 11. Global Vasculitis Treatment Market Size, by Disease Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Vasculitis Treatment Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Vasculitis Treatment Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Vasculitis Treatment Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Vasculitis Treatment Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Vasculitis Treatment Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Vasculitis Treatment Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Vasculitis Treatment Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Vasculitis Treatment Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Vasculitis Treatment Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Vasculitis Treatment Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Vasculitis Treatment Market Segmentation & Coverage
TABLE 2. Global Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 3. Global Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 4. Global Biologics Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Biologics Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Biologics Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Rituximab Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Rituximab Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Rituximab Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Tumor Necrosis Factor Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Tumor Necrosis Factor Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Tumor Necrosis Factor Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Corticosteroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Corticosteroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Corticosteroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Immunosuppressants Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Immunosuppressants Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Immunosuppressants Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Azathioprine Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Azathioprine Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Azathioprine Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Cyclophosphamide Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Cyclophosphamide Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Cyclophosphamide Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Methotrexate Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Methotrexate Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Methotrexate Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Mycophenolate Mofetil Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Mycophenolate Mofetil Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Mycophenolate Mofetil Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Plasma Exchange Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Plasma Exchange Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Plasma Exchange Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 35. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 45. Global ANCA Associated Vasculitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global ANCA Associated Vasculitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global ANCA Associated Vasculitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Behcet Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Behcet Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Behcet Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Giant Cell Arteritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Giant Cell Arteritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Giant Cell Arteritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global IgA Vasculitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global IgA Vasculitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global IgA Vasculitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Takayasu Arteritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Takayasu Arteritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Takayasu Arteritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 61. Global Ambulatory Care Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Ambulatory Care Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Ambulatory Care Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Specialty Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Specialty Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Specialty Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 74. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Vasculitis Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Europe Vasculitis Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Europe Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 86. Europe Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 87. Europe Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 88. Europe Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 89. Europe Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 90. Europe Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 91. Europe Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Vasculitis Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 99. Asia-Pacific Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 100. North America Vasculitis Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. North America Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 102. North America Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 103. North America Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 104. North America Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 105. North America Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 106. North America Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 107. North America Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 108. Latin America Vasculitis Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Latin America Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 110. Latin America Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 111. Latin America Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 112. Latin America Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 113. Latin America Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 114. Latin America Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 115. Latin America Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 116. Middle East Vasculitis Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Middle East Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 118. Middle East Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 119. Middle East Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 120. Middle East Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 121. Middle East Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 122. Middle East Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 123. Middle East Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. Africa Vasculitis Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 125. Africa Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 126. Africa Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 127. Africa Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 128. Africa Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 129. Africa Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 130. Africa Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 131. Africa Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. Global Vasculitis Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. NATO Vasculitis Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. NATO Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 135. NATO Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 136. NATO Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 137. NATO Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 138. NATO Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 139. NATO Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 140. NATO Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. G7 Vasculitis Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. G7 Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 143. G7 Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 144. G7 Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 145. G7 Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 146. G7 Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 147. G7 Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 148. G7 Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 149. European Union Vasculitis Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 150. European Union Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 151. European Union Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 152. European Union Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 153. European Union Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 154. European Union Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 155. European Union Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 156. European Union Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 157. BRICS Vasculitis Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 158. BRICS Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 159. BRICS Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 160. BRICS Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 161. BRICS Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 162. BRICS Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 163. BRICS Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 164. BRICS Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 165. ASEAN Vasculitis Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 166. ASEAN Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 167. ASEAN Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 168. ASEAN Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 169. ASEAN Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 170. ASEAN Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 171. ASEAN Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 172. ASEAN Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 173. GCC Vasculitis Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 174. GCC Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 175. GCC Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 176. GCC Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 177. GCC Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 178. GCC Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 179. GCC Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. GCC Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 181. Global Vasculitis Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 182. United States Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 183. United States Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 184. United States Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 185. United States Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 186. United States Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 187. United States Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 188. United States Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 189. United States Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 190. China Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 191. China Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 192. China Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 193. China Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 194. China Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 195. China Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 196. China Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 197. China Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 198. Germany Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 199. Germany Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 200. Germany Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 201. Germany Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 202. Germany Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 203. Germany Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 204. Germany Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 205. Germany Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 206. Japan Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 207. Japan Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 208. Japan Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 209. Japan Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 210. Japan Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 211. Japan Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 212. Japan Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 213. Japan Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 214. United Kingdom Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 215. United Kingdom Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 216. United Kingdom Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 217. United Kingdom Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 218. United Kingdom Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 219. United Kingdom Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 220. United Kingdom Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. United Kingdom Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 222. India Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 223. India Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 224. India Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 225. India Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 226. India Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 227. India Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 228. India Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 229. India Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 230. France Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 231. France Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 232. France Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 233. France Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 234. France Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 235. France Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 236. France Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 237. France Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 238. Canada Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 239. Canada Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 240. Canada Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 241. Canada Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 242. Canada Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 243. Canada Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 244. Canada Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 245. Canada Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 246. Brazil Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 247. Brazil Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 248. Brazil Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 249. Brazil Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 250. Brazil Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 251. Brazil Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 252. Brazil Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 253. Brazil Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 254. Mexico Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 255. Mexico Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 256. Mexico Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 257. Mexico Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 258. Mexico Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 259. Mexico Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 260. Mexico Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 261. Mexico Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 262. Italy Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 263. Italy Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 264. Italy Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 265. Italy Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 266. Italy Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 267. Italy Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 268. Italy Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 269. Italy Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 270. Spain Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 271. Spain Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 272. Spain Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 273. Spain Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 274. Spain Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 275. Spain Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 276. Spain Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 277. Spain Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 278. Australia Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 279. Australia Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 280. Australia Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 281. Australia Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 282. Australia Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 283. Australia Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 284. Australia Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 285. Australia Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 286. South Korea Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 287. South Korea Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 288. South Korea Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 289. South Korea Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 290. South Korea Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 291. South Korea Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 292. South Korea Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 293. South Korea Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 294. Russia Vasculitis Treatment Market Size, 2017-2032 (USD Million)
TABLE 295. Russia Vasculitis Treatment Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 296. Russia Vasculitis Treatment Market Size, by Biologics, 2017-2032 (USD Million)
TABLE 297. Russia Vasculitis Treatment Market Size, by Immunosuppressants, 2017-2032 (USD Million)
TABLE 298. Russia Vasculitis Treatment Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 299. Russia Vasculitis Treatment Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 300. Russia Vasculitis Treatment Market Size, by End User, 2017-2032 (USD Million)
TABLE 301. Russia Vasculitis Treatment Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 302. Global Vasculitis Treatment Market Share, by Key Player, 2025
TABLE 303. Global Vasculitis Treatment Market, Key Experts

Companies Mentioned

  • Amgen Inc.
  • F. Hoffmann-La Roche AG
  • GSK plc
  • AstraZeneca PLC
  • CSL Limited
  • Kissei Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Celltrion, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Fresenius SE & Co. KGaA
  • Sandoz Group AG
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Grifols, S.A.
  • Octapharma AG
  • Biogen Inc.
  • Johnson & Johnson
  • Novartis AG
  • Sanofi SA
  • Kedrion S.p.A.
  • Amneal Pharmaceuticals, Inc.
  • Bayer AG
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bristol Myers Squibb Company
  • Dr. Reddy’s Laboratories Limited
  • InflaRx GmbH
  • Intas Pharmaceuticals Limited
  • Kyverna Therapeutics, Inc.
  • Lupin Limited
  • Regeneron Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Limited
  • UCB S.A.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.75 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.39 Billion
Compound Annual Growth Rate5.3%
Regions CoveredGlobal
No. of Companies Mentioned33

Related Topics

Related Reports

Vasculitis Treatment - Global Strategic Business Report - Product Image

Vasculitis Treatment - Global Strategic Business Report

  • Report
  • 308 Pages
  • Global
From
Vasculitis Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis by Drug Class (Corticosteroids, Immunosuppressants, Biologics), Disease Type, Route of Administration, Distribution Channel - Product Image

Vasculitis Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis by Drug Class (Corticosteroids, Immunosuppressants, Biologics), Disease Type, Route of Administration, Distribution Channel

  • Report
  • 160 Pages
  • Global
From
Immunoglobulin a IgA Vasculitis Market Report 2026 - Product Image

Immunoglobulin a IgA Vasculitis Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Report 2026 - Product Image

Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Report 2026

  • Report
  • 250 Pages
  • Global
From
2025 Global Forecast for Vasculitis Treatment Market (2026-2031): High Tech Outlook Report - Product Image

2025 Global Forecast for Vasculitis Treatment Market (2026-2031): High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From

About the Vasculitis Drug Market

Vasculitis is a group of diseases that cause inflammation of the blood vessels. It can affect any organ in the body, but is most commonly seen in the heart, lungs, and kidneys. Vasculitis drugs are used to treat the inflammation and reduce the risk of organ damage. These drugs are typically immunosuppressants, which work by suppressing the immune system and reducing inflammation. Common vasculitis drugs include corticosteroids, cyclophosphamide, and methotrexate. In addition to these drugs, there are also biologic agents, such as rituximab and tocilizumab, which are used to treat more severe cases of vasculitis. These drugs are designed to target specific parts of the immune system, and are often used in combination with other treatments. The vasculitis drug market is an important part of the cardiovascular drug market, as it provides treatments for a wide range of conditions. Companies in this market include Pfizer, Merck, AbbVie, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.